Evidence map›Paper›PMID 25652737›Full record

ReviewLeukemia2015

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

N C P Cross, H E White, D Colomer, H Ehrencrona, L Foroni, E Gottardi, T Lange, T Lion, K Machova Polakova, S Dulucq and 11 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 2 pooled it
27.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 2 syntheses or guidelines pooled it, 338 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 12 countries.

N C P Cross1] Faculty of Medicine, University of Southampton, Southampton, UK [2] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK.
H E White1] Faculty of Medicine, University of Southampton, Southampton, UK [2] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK.
D ColomerHematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
H EhrencronaDepartment of Clinical Genetics, Laboratory Medicine, Lund University, Lund, Sweden.
L ForoniImperial Molecular Pathology Laboratory, Centre for Haematology, Imperial College London, London, UK.
E GottardiDepartment of Clinical and Biological Science, University of Turin, Turin, Italy.
T LangeAbteilung für Hämatologie und internistische Onkologie, Universität Leipzig, Leipzig, Germany.
T LionChildren's Cancer Research Institute/LabDia Labordiagnostik and Medical University, Vienna, Austria.
K Machova PolakovaInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
S DulucqLaboratoire Hematologie, CHU Bordeaux, Hematopoiese Leucemique et Cibles Therapeutiques, INSERM U1035, Université Bordeaux, Bordeaux, France.
G MartinelliDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
E Oppliger LeibundgutMolecular Diagnostics Laboratory, Department of Hematology, University Hospital Bern, Bern, Switzerland.
N PallisgaardKlinisk Biokemi, Vejle Sygehus, Vejle, Denmark.
G BarbanyDepartment of Molecular Medicine and Surgery, Clinical Genetics, Karolinska Institutet, Stockholm, Sweden.
T SachaHematology Department, Jagiellonian University, Krakow, Poland.
R TalmaciHematology Department - Fundeni Clinical Institute, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.
B IzzoDepartment of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy.
G SaglioDepartment of Clinical and Biological Science, University of Turin, Turin, Italy.
F Pane1] Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy [2] CEINGE - Biotecnologie Avanzate, Naples, Italy.
M C MüllerIII. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany.
A HochhausAbteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Salisbury District Hospital · GBUniversity of Naples Federico II · ITUniversity of Turin · ITCancer Research Institute of the Slovak Academy of Sciences · SKConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESImperial College London · GBInserm · FRInstitute of Haematology and Blood Transfusion · CZInstitutul Clinic Fundeni · ROJagiellonian University · PLJena University Hospital · DEKarolinska Institutet · SELeipzig University · DELund University · SEUniversity Hospital Heidelberg · DEUniversity Hospital of Bern · CHUniversity of Bologna · ITVejle Sygehus · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.

Indexed as

Gene Expression Regulation, LeukemicCalibrationEuropeFusion Proteins, bcr-ablGene Expression ProfilingGenetic VariationHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLimit of DetectionPolymerase Chain ReactionProtein-Tyrosine KinasesReproducibility of ResultsTreatment OutcomeBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablProtein-Tyrosine Kinases

Identifiers

PMID25652737
PMCPMC4430701
OpenAlexW2077812841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.